| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 271 | 2 | 37 | 43 | 32 | 1.477 | 9 | 90 | 59 | 10 |
| Total Expenses - EUR | 3.229 | 1.393 | 274 | 1.002 | 467 | 4.382 | 1.221 | 685 | 553 | 724 |
| Gross Profit/Loss - EUR | -2.958 | -1.391 | -237 | -960 | -435 | -2.905 | -1.212 | -595 | -494 | -714 |
| Net Profit/Loss - EUR | -2.958 | -1.391 | -237 | -960 | -435 | -2.905 | -1.212 | -595 | -494 | -714 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Poly Pid Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 849 | 198 | 1.026 | 737 | 1.751 | 655 | 616 | 617 | 616 | 612 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 849 | 198 | 1.026 | 737 | 1.751 | 655 | 616 | 617 | 616 | 612 |
| Shareholders Funds | -6.080 | -7.409 | -7.520 | -8.299 | -8.573 | -11.274 | -12.236 | -12.869 | -13.324 | -13.964 |
| Social Capital | 450 | 445 | 438 | 473 | 464 | 496 | 485 | 487 | 485 | 482 |
| Debts | 6.929 | 7.607 | 8.546 | 9.036 | 10.324 | 11.929 | 12.852 | 13.487 | 13.940 | 14.576 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7022 - 7022" | |||||||||
| CAEN Financial Year |
7022
|
|||||||||
Comments - Poly Pid Pharm Srl